| Title |
Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer The PRONOUNCE Trial Study Design
|
|---|---|
| Published in |
JACC: CardioOncology, March 2020
|
| DOI | 10.1016/j.jaccao.2020.01.004 |
| Pubmed ID | |
| Authors |
Chiara Melloni, Susan F. Slovin, Allan Blemings, Shaun G. Goodman, Christopher P. Evans, Jan Nilsson, Deepak L. Bhatt, Konstantin Zubovskiy, Tine K. Olesen, Klaus Dugi, Noel W. Clarke, Celestia S. Higano, Matthew T. Roe, PRONOUNCE Investigators |
X Demographics
The data shown below were collected from the profiles of 57 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 13 | 23% |
| Brazil | 3 | 5% |
| Spain | 3 | 5% |
| Canada | 2 | 4% |
| United Kingdom | 1 | 2% |
| Chile | 1 | 2% |
| Italy | 1 | 2% |
| Japan | 1 | 2% |
| Colombia | 1 | 2% |
| Other | 3 | 5% |
| Unknown | 28 | 49% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 43 | 75% |
| Practitioners (doctors, other healthcare professionals) | 6 | 11% |
| Scientists | 5 | 9% |
| Science communicators (journalists, bloggers, editors) | 3 | 5% |
Mendeley readers
The data shown below were compiled from readership statistics for 57 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 57 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 7 | 12% |
| Unspecified | 5 | 9% |
| Student > Master | 5 | 9% |
| Lecturer | 4 | 7% |
| Other | 4 | 7% |
| Other | 9 | 16% |
| Unknown | 23 | 40% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 21% |
| Unspecified | 5 | 9% |
| Nursing and Health Professions | 4 | 7% |
| Computer Science | 2 | 4% |
| Business, Management and Accounting | 2 | 4% |
| Other | 7 | 12% |
| Unknown | 25 | 44% |
Attention Score in Context
This research output has an Altmetric Attention Score of 34. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 October 2021.
All research outputs
#1,207,263
of 25,655,374 outputs
Outputs from JACC: CardioOncology
#108
of 468 outputs
Outputs of similar age
#31,706
of 406,003 outputs
Outputs of similar age from JACC: CardioOncology
#5
of 29 outputs
Altmetric has tracked 25,655,374 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 468 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 28.2. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 406,003 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 29 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 82% of its contemporaries.